GlassScriptPhysician profile
Brooke A Davis
NPI 1003463969
$10,594.11
in general payments reported to CMS, 2019-2025
78 companies · $3,110 in 2025
The $3,110 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $888 · 2022: $2,152 · 2023: $2,171 · 2024: $2,274 · 2025: $3,110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,329 · Education: $225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,329.42 |
| Education | $224.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $951.51 | 2022-2025 | Kisqali, Piqray |
| Janssen Biotech, INC. | $629.57 | 2021-2025 | Rybrevant, Carvykti, Darzalex |
| E.R. Squibb & Sons, L.L.C. | $451.14 | 2021-2025 | Opdivo, Reblozyl, Eliquis |
| Puma Biotechnology, INC. | $433.91 | 2021-2024 | |
| Pfizer INC. | $371.62 | 2021-2025 | |
| Lilly USA, LLC | $340.41 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Incyte Corporation | $330.69 | 2021-2025 | Jakafi, Niktimvo, Monjuvi |
| Astrazeneca Pharmaceuticals LP | $313.88 | 2021-2025 | Imfinzi, Enhertu, Lynparza |
| Eisai INC. | $304.30 | 2021-2024 | |
| Amgen INC. | $300.81 | 2021-2023 | Xgeva, Vectibix, Nplate |
| Aveo Pharmaceuticals, INC. | $269.21 | 2021-2025 | Fotivda |
| Merck Sharp & Dohme LLC | $263.99 | 2021-2025 | Keytruda, Reblozyl, Lynparza |
| Genzyme Corporation | $244.27 | 2021-2025 | |
| Astellas Pharma US INC | $234.09 | 2023-2025 | Padcev, Xtandi, Xospata |
| Karyopharm Therapeutics INC. | $223.04 | 2021-2025 | Xpovio |
Show all 78 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $216.84 | 2023-2025 | Orserdu, Elzonris |
| Alexion Pharmaceuticals, INC. | $206.08 | 2023-2025 | Ultomiris |
| Servier Pharmaceuticals LLC | $197.17 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $193.90 | 2021-2025 | Fruzaqla, Iclusig, Ninlaro |
| Novocure INC. | $177.78 | 2021-2025 | Optune Gio, Optune Lua (Novottf-200t), Optune |
| Gilead Sciences, INC. | $177.60 | 2022-2025 | Trodelvy |
| Adc Therapeutics America, INC. | $177.01 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.49 | 2021-2025 | Gilotrif |
| Exelixis INC. | $158.57 | 2022-2025 | Cabometyx |
| Celgene Corporation | $144.31 | 2021-2024 | Pomalyst |
| Daiichi Sankyo INC. | $138.89 | 2022-2025 | Enhertu, Datroway |
| Array Biopharma INC | $136.99 | 2021-2025 | Braftovi, Mektovi, Tukysa |
| Seagen INC. | $136.43 | 2021-2024 | Padcev |
| Sobi, INC | $131.09 | 2022-2025 | |
| Pharmacosmos Therapeutics INC. | $130.68 | 2023-2025 | Monoferric, Cosela |
| Regeneron Healthcare Solutions, INC. | $130.55 | 2022-2025 | Libtayo |
| Janssen Scientific Affairs, LLC | $129.86 | 2021-2025 | Erleada, Balversa, Akeega |
| Alnylam Pharmaceuticals INC. | $114.69 | 2021-2024 | Givlaari |
| Beone Medicines USA, INC. | $105.74 | 2025 | Tevimbra, Brukinsa |
| Genentech USA, INC. | $104.51 | 2022-2025 | Itovebi, Polivy, Venclexta |
| Bayer Healthcare Pharmaceuticals INC. | $93.14 | 2022-2024 | |
| Tersera Therapeutics LLC | $82.40 | 2022-2025 | Quzyttir, Xermelo |
| Azurity Pharmaceuticals, INC. | $77.32 | 2024-2025 | Danziten, Vivimusta |
| Genmab U.S., INC. | $70.15 | 2025 | Epkinly, Tivdak |
| Glaxosmithkline, LLC. | $69.57 | 2023-2025 | Zejula, Jemperli, Ojjaara |
| Amneal Pharmaceuticals LLC | $64.99 | 2024 | Avastin |
| Abbvie INC. | $64.83 | 2022-2025 | |
| Accord Healthcare, INC. | $64.41 | 2023-2025 | |
| Morphosys, US INC. | $61.26 | 2021-2023 | Monjuvi |
| Emd Serono, INC. | $60.14 | 2021-2025 | |
| Coherus Oncology, INC. | $56.51 | 2021-2023 | |
| Fresenius Kabi USA, LLC | $55.06 | 2023-2025 | Stimufend |
| Pharmaessentia USA Corporation | $49.78 | 2022-2025 | Besremi |
| Kite Pharma, INC. | $49.55 | 2025 | Yescarta |
| Jazz Pharmaceuticals INC. | $49.47 | 2025 | |
| Springworks Therapeutics, INC. | $49.39 | 2025 | Gomekli |
| Deciphera Pharmaceuticals INC. | $48.72 | 2021-2022 | |
| Blueprint Medicines Corporation | $46.41 | 2023-2025 | Ayvakit |
| Adaptive Biotechnologies Corporation | $45.11 | 2025 | Clonoseq |
| Taiho Oncology, INC. | $42.50 | 2022-2025 | |
| Acceleron Pharma, INC. | $40.79 | 2021 | |
| Mirati Therapeutics, INC. | $40.79 | 2023 | Krazati |
| Syndax Pharmaceuticals, INC. | $40.76 | 2025 | |
| Acrotech Biopharma INC. | $37.85 | 2023-2025 | Beleodaq |
| Janssen Pharmaceuticals, INC | $37.77 | 2023-2024 | Xarelto |
| Pharmacyclics LLC, An Abbvie Company | $36.15 | 2021-2022 | |
| Kyowa Kirin, INC. | $34.57 | 2023-2025 | Poteligeo |
| Ge Healthcare | $33.82 | 2022 | |
| Biocon Biologics INC | $32.41 | 2025 | Ogivri |
| Dendreon Pharmaceuticals LLC | $32.08 | 2024 | Provenge |
| Progenics Pharmaceuticals, INC. | $29.37 | 2023 | Pylarify |
| Rigel Pharmaceuticals, INC. | $29.35 | 2023 | Rezlidhia, Tavalisse |
| Epizyme, INC. | $27.69 | 2021 | |
| Tempus Ai, INC | $25.89 | 2025 | Xt Cdx |
| Spectrum Pharmaceuticals INC. | $24.00 | 2023 | Rolvedon |
| Tactile Systems Technology INC | $22.15 | 2024 | Entre Plus, Flexitouch Plus |
| Tg Therapeutics, INC. | $22.07 | 2021 | |
| Bard Peripheral Vascular, INC. | $20.20 | 2024 | Trek |
| Ferring Pharmaceuticals INC. | $17.97 | 2025 | Adstiladrin |
| G1 Therapeutics, INC. | $17.96 | 2022 | |
| Beigene USA, INC. | $17.47 | 2024 | Brukinsa |
| Organon LLC | $15.50 | 2021 | |
| Shield Therapeutics INC | $13.17 | 2023 | Accrufer |
Drugs and devices associated with these payments
Kisqali $273Lenvima $213Pluvicto $204Rybrevant $195Orserdu $192Ultomiris $177Padcev $169Erleada $167Xtandi $161Jaypirca $155Jakafi $155Fotivda $144Carvykti $141Opdivo $135Verzenio $135Reblozyl $135Darzalex $132Cabometyx $127Keytruda $119Enhertu $119Xpovio $118Orgovyx $114Talvey $112Monoferric $111Akeega $105Braftovi $105Mektovi $105Imbruvica $94.59Lutathera $94.08Tecvayli $93.96Libtayo $92.86Sarclisa $92.33Talzenna $92.05Vectibix $89.31Nplate $89.31Xgeva $89.31Tibsovo $88.04Pomalyst $86.02Balversa $83.73Trodelvy $82.83Scemblix $79.05Epkinly $72.81Voranigo $71.39Elrexfio $69.53Avastin $64.99Piqray $64.29Imfinzi $62.53Brukinsa $62.43Tevimbra $60.78Monjuvi $60.76Retevmo $58.69Zynlonta $58.12Tukysa $57.78Vonjo $56.60Danziten $55.86Stimufend $55.06Givlaari $52.74Zejula $51.24Nubeqa $50.51Xofigo $50.51Yescarta $49.55Gilotrif $48.84Fabhalta $48.42Idhifa $47.15Ayvakit $46.41Fruzaqla $46.17Lynparza $46.05Clonoseq $45.11Camcevi $43.37Iclusig $41.88Krazati $40.79Datroway $40.59Beleodaq $37.85Xarelto $37.77Xospata $37.70Quzyttir $37.42Itovebi $35.42Jemperli $35.34Poteligeo $34.57Ogivri $32.41Provenge $32.08Lorbrena $30.20Besponsa $29.71Bosulif $29.71Pylarify $29.37Rezlidhia $29.35Tavalisse $29.35Tabrecta $29.30Xermelo $28.26Optune Gio $27.98Ninlaro $26.84Niktimvo $26.70Exkivity $26.61Besremi $26.12Xt Cdx $25.89Wayrilz $25.66Elzonris $24.59Gomekli $24.40Rolvedon $24.00Lonsurf $23.55
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.